RCOphth invited to address issues of capacity at a meeting of the All Party Parliamentary Group for Eye Health and Visual Impairment.
Miss Corbett commented, ‘The demand on eye services has increased by 30% over the last five years in the UK. This is largely due to an ageing population with the associated chronic diseases such as glaucoma, age related macular degeneration (AMD) and diabetes.’
Professor Carrie MacEwen and Professor Andrew Lotery co-author the editorial ‘What is stopping the NHS from using bevacizumab for macular degeneration and other retinal disorders?’, published online on BMJ, calls for UK regulatory bodies to review and appraise use of bevacizumab for use in AMD treatment.
Fluocinolone acetonide intravitreal implant for treating chronic DMO after inadequate response to prior therapy
College statement on NICE guidance TA 301 – Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after inadequate response to prior therapy (rapid review of technology appraisal guidance 271) December 2013
Use of Avastin (bevacizumab) in age related macular degeneration
College statement on the use of Avastin (bevacizumab) in age related macular degeneration December 2014
Statement in response to NICE announcing their positive final guidance for Eylea® for the treatment of macular oedema secondary to CRVO
Statement from The Royal College of Ophthalmologists in response to NICE announcing their positive final guidance for Eylea® for the treatment of macular oedema secondary to CRVO February 2014